FDA Refuses-to-File Moderna’s 40,000-Patient mRNA Flu Vaccine Application
The FDA issued a refusal-to-file letter for Moderna’s new mRNA flu vaccine application, citing deficiencies in its 40,000-participant clinical trial design and conduct. The agency objected to trial protocol deviations and data integrity issues, delaying potential U.S. authorization of the vaccine.
1. FDA Refusal-to-File Letter Details
Moderna received a refusal-to-file letter from the FDA for its proposed mRNA-based influenza vaccine, indicating the agency would not review the application in its current form. The letter specifically flagged inadequate documentation and protocol deviations in the pivotal clinical trial submission.
2. Clinical Trial Conduct Concerns
The 40,000-person trial compared Moderna’s mRNA flu vaccine to a standard quadrivalent shot, but the FDA identified inconsistencies in site monitoring, data collection and statistical analysis plans. These deficiencies raised questions about the reliability of safety and efficacy endpoints.
3. Impact on Product Launch and Finances
The refusal stalls Moderna’s plan to expand its mRNA platform beyond COVID-19, potentially delaying projected revenue growth from seasonal flu vaccine sales. Analysts may revise near-term guidance as the company absorbs development delays and regulatory costs.
4. Next Steps and Timeline Expectations
Moderna must address the FDA’s concerns by amending trial protocols, supplying additional data or conducting supplementary studies before resubmission. A revised application could be filed later this year, but full U.S. authorization may not occur until 2027.